Effect of Oral Allopurinol in Elevated Liver Enzyme Reduction in Pediatric Acute Lymphoblastic Leukemia During Maintenance Therapy
Novelty in Biomedicine,
Vol. 14 No. 1 (2026),
8 February 2026
,
Page 1-12
https://doi.org/10.22037/nbm.v14i1.48158
Abstract
Background: Acute lymphoid leukemia (ALL) represents a prevalent form of cancer in pediatric populations. Mercaptopurine is one of the proposed treatments for these patients. This treatment may cause multiple side effects, including liver-related effects. Allopurinol has been proposed as a means to mitigate hepatotoxicity, but the previous studies in this regard remain scarce. This study aimed to investigate the effect of allopurinol on preventing increases in liver enzymes in children with ALL during the maintenance phase of drug treatment.
Materials and Methods: This is a double-blind clinical trial conducted on children with ALL receiving maintenance treatment with mercaptopurine during the maintenance phase of the disease. Patients were categorized into two groups. The initial cohort of 25 individuals was administered mercaptopurine tablets in combination with allopurinol tablets. The second group, comprising an equivalent number of patients, was administered mercaptopurine tablets and a placebo. Laboratory studies were evaluated. The patients' data were analyzed at the 0.05 significance level.
Results: The mean age in group A was 7.64 ± 3.78 years, while in group B it was 6.92 ± 3.19 years. In group A, the proportion of boys was 44%, whereas in group B, it was 72%. In both groups, the majority of patients tolerated less than 75 mg of mercaptopurine per body surface area, whereas, for methotrexate, most patients tolerated less than 20 mg per body surface area. Allopurinol significantly reduced mercaptopurine-induced hepatotoxicity in pediatric patients with ALL (P-value < 0.05). Allopurinol significantly reduced alanine transaminase (ALT) and aspartate aminotransferase (AST) levels compared to placebo (P-value<0.05). The intra-group analysis indicated that allopurinol significantly reduced enzyme levels over time (all P-values < 0.05).
Conclusion: Allopurinol reduces hepatotoxicity in ALL patients receiving mercaptopurine.
- Allopurinol
- Mercaptopurine
- Acute lymphoid leukemia
- Pediatric
How to Cite
References
1. Puckett Y, Chan O. Acute lymphocytic leukemia. 2017.
2. DeRenzo C, Krenciute G, Gottschalk S, editors. The Landscape of CAR T cells beyond ALL for Pediatric Solid Tumors. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting; 2018.
3. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood, The Journal of the American Society of Hematology. 2012;120(14):2807-16.
4. von Stackelberg A, Völzke E, Kühl J-S, Seeger K, Schrauder A, Escherich G, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group. European journal of cancer. 2011;47(1):90-7.
5. Peters C, Dalle J-H, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. Journal of Clinical Oncology. 2021;39(4):295-307.
6. Rank CU, Lynggaard LS, Als-Nielsen B, Stock W, Toft N, Nielsen OJ, et al. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database of Systematic Reviews. 2020(10).
7. Biondi A, Schrappe M, Di Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. Efficacy and safety of imatinib on top of BFM-like chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ ALL). The EsPhALL study. Blood. 2011;118(21):873.
8. Higgerson K, Flatt T. Skin toxicity due to mercaptopurine in maintenance therapy among children with acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology. 2023;45(4):e514-e7.
9. Adam de Beaumais T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K, et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. British journal of clinical pharmacology. 2011;71(4):575-84.
10. Qurie A, Preuss CV, Musa R. Allopurinol. 2018.
11. Conneely SE, Cooper SL, Rau RE. Use of allopurinol to mitigate 6-mercaptopurine associated gastrointestinal toxicity in acute lymphoblastic leukemia. Frontiers in Oncology. 2020;10:1129.
12. Blaker P, Arenas-Hernandez M, Smith M, Shobowale-Bakre E, Fairbanks L, Irving P, et al. Mechanism of allopurinol induced TPMT inhibition. Biochemical pharmacology. 2013;86(4):539-47.
13. Bolia R, Rajanayagam J, Hardikar W. Lower 6-MMP/6-TG ratio may be a therapeutic target in pediatric autoimmune hepatitis. Journal of Pediatric Gastroenterology and Nutrition. 2018;67(6):695-700.
14. Gallagher S, Kumar T, Long A, Leroy K. S3616 The Concomitant Use of Allopurinol and Azathioprine Leading to Dangerous Myelosuppression in a Patient with Ulcerative Colitis. Official journal of the American College of Gastroenterology| ACG. 2021;116:S1481.
15. Topley J, Benson J, Squier M, Chessells J. Hepatotoxicity in the treatment of acute lymphoblastic leukaemia. Medical and Pediatric Oncology. 1979;7(4):393-9.
16. Zhang S, Chen Q, Wang Q. The use of and adherence to CTCAE v3. 0 in cancer clinical trial publications. Oncotarget. 2016;7(40):65577.
17. Shah ED, Coburn ES, Nayyar A, Lee KJ, Koliani‐Pace JL, Siegel CA. Systematic review: hepatosplenic T‐cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. Alimentary pharmacology & therapeutics. 2020;51(5):527-33.
18. Martins R, Carmona C, George B, Epstein J. Management of Crohn’s disease: Summary of updated NICE guidance. Bmj. 2019;367.
19. Bayoumy AB, Simsek M, Seinen ML, Mulder CJ, Ansari A, Peters GJ, et al. The continuous rediscovery and the benefit–risk ratio of thioguanine, a comprehensive review. Expert Opinion on Drug Metabolism & Toxicology. 2020;16(2):111-23.
20. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. European journal of clinical pharmacology. 2008;64:753-67.
21. Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. Journal of Crohn's and Colitis. 2010;4(5):546-52.
22. Seinen ML, van Asseldonk DP, de Boer N, Losekoot N, Smid K, Mulder C, et al. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. Journal of Crohn's and Colitis. 2013;7(10):812-9.
23. Vasudevan A, Con D, De Cruz P, Sparrow MP, Friedman AB, Garg M, et al. Clinical trial: combination allopurinol‐thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study). Alimentary Pharmacology & Therapeutics. 2024;59(4):504-14.
24. Kamojjala R, Bostrom B. Allopurinol to prevent mercaptopurine adverse effects in children and young adults with acute lymphoblastic leukemia. Journal of Pediatric Hematology/Oncology. 2021;43(3):95-100.
25. Vasta LM, Zanetti RC, Parekh DS, Warwick AB, Lieuw K. A retrospective review of mercaptopurine metabolism reveals high rate of patients with suboptimal metabolites successfully corrected with allopurinol. Journal of pediatric hematology/oncology. 2021;43(7):e1003-e9.
26. Cohen G, Cooper S, Sison EA, Annesley C, Bhuiyan M, Brown P. Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6‐mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity. Pediatric blood & cancer. 2020;67(11):e28360.
- Abstract Viewed: 53 times
- pdf Downloaded: 41 times